.svg){kind=icon}
Market research firms peg vision therapy at $1.4 to $3.2 billion. But when you add up the sub-markets they track separately, the actual addressable opportunity is closer to $10 billion — and most of it is unserved.
The vision therapy market has a measurement problem. Depending on which research firm you ask, you will get a number somewhere between $1.4 billion (Grand View Research's 2028 projection) and $3.2 billion (Market Research Future's earlier estimate). These figures show up in investor decks, practice management seminars, and industry conference slides. They are also almost certainly too low.
The issue is not that the research firms are wrong about what they measured. It is that the vision therapy market does not exist as a single, cleanly bounded category. It sprawls across at least five distinct sub-markets — pediatric binocular vision disorders, neuro-optometric rehabilitation, sports vision training, digital therapeutics, and the emerging computer vision syndrome treatment space — each tracked by different analysts under different headings. Add them up and you get a picture that should change how optometrists, investors, and policymakers think about this field.
The Sub-Markets Nobody Is Adding Together
Here is what the data actually shows when you pull the pieces into one frame.
Amblyopia and pediatric binocular vision treatment is the largest single segment. The global amblyopia treatment market was valued at approximately $6.7 billion in 2025, with projections reaching $8.6 billion by 2032 at a 3.8 percent compound annual growth rate. This includes surgical, optical, and therapeutic approaches — but vision therapy's share is growing fast. Digital therapeutics like AmblyoPlay and Luminopia (the first FDA-cleared digital therapeutic for amblyopia) now account for roughly 45 percent of treatment modalities, and most of those digital tools are built on vision therapy principles. The strabismus treatment apparatus market adds another $1.65 billion, with the non-surgical segment — including vision therapy and prism correction — showing the strongest growth trajectory.
Neuro-optometric rehabilitation defies easy market sizing because it barely exists as a formal market category, despite staggering demand. The World Health Organization estimates 69 million traumatic brain injuries occur globally each year. Studies consistently show that 90 percent of TBI patients experience visual dysfunction — vergence disorders, accommodative problems, saccadic impairment, visual field deficits. At an average treatment cost of $3,000 to $4,000 per patient, even capturing 5 percent of the US TBI population (approximately 2.8 million annually) implies a domestic addressable market north of $400 million. The actual served market is a fraction of that, constrained by the same provider shortage and insurance barriers that plague the rest of vision therapy.
Sports vision training was valued at $500 million in 2024 and is projected to reach $1.1 billion by 2032, growing at a 10 percent CAGR. Professional teams across the NFL, MLB, NBA, and Premier League now invest in visual performance programs. The trickle-down to youth sports and weekend athletes is just beginning.
VR and digital vision therapy platforms represent the fastest-growing segment. The virtual reality vision therapy market hit $1.49 billion in 2025 and is growing at a remarkable 21.2 percent CAGR, projected to reach $3.87 billion by 2030. The adjacent vision therapy software market is valued at $1.2 billion in 2026, with North America commanding over 40 percent of global share.
Computer vision syndrome treatment is harder to isolate but impossible to ignore. With 75 percent of digital device users reporting symptoms according to the American Optometric Association, and the broader vision care market now valued at $146 billion partly driven by screen-related complaints, even a conservative slice of CVS-related therapeutic spending adds hundreds of millions.
The Real Number — And Why It Matters
When you stack these sub-markets, the total addressable vision therapy opportunity in its broadest definition is somewhere between $8 billion and $12 billion globally, with the US accounting for roughly 35 to 40 percent. That is four to eight times the figure most commonly cited in industry presentations.
Why does this matter beyond academic precision? Because the "vision therapy is a small niche" framing has real consequences. It discourages investment in training programs, constrains insurance negotiations, and keeps policymakers from prioritizing vision screening reform. When you think the market is $1.4 billion, it looks like a specialty interest. When you see it as a $10 billion-plus opportunity with massive unmet demand, the calculus changes.
Consider the supply-side constraint. Out of roughly 44,000 practicing optometrists in the United States, fewer than 1,000 offer in-office vision therapy. Less than 1 percent of the profession serves a market that, by the numbers, could support ten times as many providers. The bottleneck is not demand — parents are desperately searching for convergence insufficiency treatment, concussion patients need visual rehabilitation, and professional athletes want every visual edge they can find. The bottleneck is capacity.
Five Forces Driving Growth
Several converging trends suggest the market will grow faster than historical rates would predict.
Digital therapeutics are lowering the access barrier. Luminopia's FDA clearance for amblyopia treatment proved that digital vision therapy could navigate the regulatory pathway. VR-based platforms are making therapy sessions available in homes, schools, and primary care offices that would never have a vision therapy suite. This does not replace in-office therapy — it extends the treatable population.
Post-COVID telehealth normalization. Tele-vision therapy went from curiosity to necessity during 2020 and never went back. Hybrid models — in-office evaluation and supervised sessions combined with home-based digital reinforcement — are becoming the standard of care in progressive practices. This extends geographic reach beyond the provider deserts that have historically limited access.
TBI awareness is expanding the patient funnel. Concussion protocols now routinely include vision assessment in professional sports, military healthcare, and increasingly in emergency medicine. Every TBI patient whose visual symptoms get properly identified is a potential vision therapy patient. The VA alone serves hundreds of thousands of veterans with TBI-related visual dysfunction.
Screen time is creating a new patient population. The computer vision syndrome epidemic is not a temporary phenomenon. As work, education, and entertainment continue their migration to screens, the population experiencing accommodative stress, vergence dysfunction, and digital eye strain will only grow. Vision therapy practices that position for this demand have a functionally unlimited patient pipeline.
AI and machine learning are personalizing treatment. The vision therapy software market's growth is fueled by platforms that use AI to customize therapy regimens, track progress objectively, and adjust difficulty in real time. This makes therapy more effective, more measurable, and more defensible to the insurance companies that have historically resisted coverage.
The Insurance Inflection Point
The biggest constraint on market growth remains insurance coverage. Vision therapy typically costs $2,000 to $6,000 for a full course of treatment, and most insurance plans cover evaluations but not therapy sessions. Families pay out of pocket, which creates obvious access disparities.
But the pressure for coverage reform is building from multiple directions. Digital therapeutics with FDA clearance are harder for insurers to classify as "experimental." Growing evidence from the CITT and subsequent trials meets the evidentiary standards insurers claim to require. And the economic case is becoming clearer: untreated convergence insufficiency in children correlates with reduced reading performance and academic achievement, which has downstream costs that eventually land on someone's balance sheet.
Several large payers have quietly expanded vision therapy coverage in the past two years, particularly for post-TBI rehabilitation and pediatric binocular vision disorders. This is not yet a flood, but the direction is unmistakable.
What This Means for Eye Care Practitioners
For optometrists considering whether to add or expand vision therapy services, the market data tells a clear story. The demand is real and growing across multiple patient populations. The supply constraint means that practices offering vision therapy face limited direct competition in most markets. The technology curve is making it more feasible to deliver therapy efficiently, including through hybrid in-office and home-based models.
The practices that will capture the most value from this expanding market are those that think beyond the traditional pediatric convergence insufficiency patient — the historical bread and butter of vision therapy. The neuro-optometric rehabilitation space is severely underserved. Sports vision training commands premium pricing. Digital eye strain is creating adult patients who would never have walked into a vision therapy practice a decade ago.
The vision therapy market is not a $1.4 billion niche. It is a constellation of overlapping, fast-growing sub-markets that collectively represent one of the largest underserved opportunities in eye care. The providers, investors, and policymakers who see the full picture will be the ones who shape what comes next.
This is the first article in a five-part series examining the vision therapy market. Upcoming installments will dive deep into each sub-market: pediatric vision therapy, neuro-optometric rehabilitation, sports vision training, and digital therapeutics.